Tioma's broad basket

Tioma hopes to show clinical POC for multiple anti-CD47 mAbs with $86M A round

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47.

President and CEO John Donovan said the round should enable Tioma to generate clinical proof of concept over the next

Read the full 502 word article

User Sign In